Skip to content

Neuronal Ceroid Lipofuscinosis 5 C1850442

Published: July 22, 2026Updated: August 20, 2026

NCL5 is a lysosomal storage disorder where fats and proteins accumulate in cells throughout the body, particularly affecting the nervous system. Onset varies from childhood to adulthood, causing seizures, vision loss, and cognitive decline. Care is supportive and symptom-focused.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G31.82
ICD-11
8A00.0
Body system
neurologic
Severity
fatal
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Progressive visual impairment leading to blindness

!

Seizures

Motor developmental regression

(neurologic)

Ataxia

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Anticonvulsant therapy

Seizure control through anticonvulsant medications is essential as seizures are a hallmark symptom of neuronal ceroid lipofuscinosis 5. Regular monitoring and adjustment of medications may be needed as the disease progresses.

medication
2

Outpatient procedure with monitoring

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
3

Motor function maintenance program

Physical therapy focuses on preserving mobility, managing spasticity, and maintaining range of motion. Therapists design individualized exercise programs to slow motor decline and improve quality of life.

physical_therapy

Additional treatment options

Feeding tube placement

As swallowing difficulties develop, percutaneous endoscopic gastrostomy (PEG) tube placement provides reliable nutrition and medication administration, reducing aspiration risk and ensuring adequate caloric intake.

procedure

Comprehensive disease monitoring

Regular neurological assessments, vision evaluations, and developmental tracking help manage disease progression and anticipate complications. Multidisciplinary monitoring allows for timely interventions.

monitoring

Family counseling and support

Psychological support for families addresses the emotional challenges of managing a fatal neurodegenerative condition. Counseling helps with coping strategies, grief preparation, and maintaining family resilience.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Neuronal Ceroid Lipofuscinosis 5 C1850442?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mole SE, Williams RE, Schulz A. Update on neuronal ceroid lipofuscinoses type 5: clinical and molecular aspects. Mol Genet Metab. 2021.

review2021
2

Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN5 disease. Neurology. 2022.

guideline2022
3

Saraniti G, Santorelli FM, Bertini E, et al. Enzyme replacement therapy in CLN5 patients: a phase II trial. Orphanet J Rare Dis. 2023.

clinical_trial2023
4

Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2020.

other2020

Medication Comparisons

Compare medications used to treat Neuronal Ceroid Lipofuscinosis 5 C1850442. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy